Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

Successful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaking presentation of Phase 2a study results at the American Urological Association Annual Meeting Manufacturing collaboration agreement with Cook MyoSite in anticipation of Lipella’s forthcoming Investigational … Read more